Alnylam Pharmaceuticals, Inc. Earnings: Waiting for Apollo
Alnylam Pharmaceuticals (NASDAQ: ALNY) reported second-quarter earnings last week -- and for the record, the company lost $118.4 million -- but without any products on the market, the focus of the earnings call was the biotech's pipeline and the potential for revenue in the not-too-distant future.
Metric
End of Q2 2017
Source: Fool.com
Pfizer Inc. Stock
€26.13
0.370%
The stock is one of the favorites of our community with 32 Buy predictions and 4 Sell predictions.
As a result the target price of 40 € shows a very positive potential of 53.08% compared to the current price of 26.13 € for Pfizer Inc..
